| Intended use |
Clinically, humanized monoclonal antibodies (IgG) and their fragments are used for in-vivo diagnostic procedures (radionuclides) and treatment for patients with various diseases. In patients, even a single dose injection of a humanized monoclonal antibody or its fragment may induce immune response directed against this foreign protein (immunogen). Also, people with autoimmune diseases, such as rheumatoid arthritis, lupus, etc. produce autoantibodies against human IgG. In the circulation, human antibody against human IgG could bind to the injected human IgG and, therefore, diminish the efficacy of either the application of the in-vivo diagnosis or treatment. Especially, the HAHA would increase the risk of an anaphylactic complication to subsequent administration of the humanized monoclonal antibody based therapy. |